Global Pompe Disease Market – Industry Trends and Forecast to 2029

Pompe Disease Market Analysis and Size

The global pompe disease market is expected to witness significant growth during the forecast period. In United States, estimated incidence are approximately 1 in 40,000 births. Males and females are equally affected by the diseases. Medical advancements which involves ongoing drug discovery, and government and non-government organizational initiatives are what that boosts the market grwoth. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global pompe disease market in the forecast period 2022-2029. The expected CAGR of global pompe disease market is tend to be around 5.0% in the mentioned forecast period. The market was valued at USD 1.4 billion in 2021, and it would grow upto USD 2.07 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Pompe disease is an autosomal recessive inherited disorder caused by the pathogenic variations in the acid alpha-glucosidase (GAA) gene. It is characterized by the abnormal build up of sugar (glycogen) inside the cells, this sugar builds up the working of different organs and tissues specifically heart, skeletal muscles and respiratory tract. Patients suffering from classic infantile form type of pompe disease are most affect patients. In infants, symptoms are generally seen in three months with rapidly muscle weakness, hypotonia, respiratory insufficiency, hypertrophic cardiomyopathy. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period

Report Scope and Market Segmentation

Global Pompe Disease Market Dynamics

Drivers

• Increased Incidence of Pompe Disease

Pompe disease affects 1 in 40,000 individuals in the U.S. It has been witnessed that the total carrier frequency (C.F.) and predicted genetic prevalence (pGP) were approximately 1.3 %  and 1:23,232, respectively. Its incidence is growing and its treatment is of great importance to the healthcare sector.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increased Research and Clinical Activities

Launching novel drugs globally will boost the demand for treatment of pompe disease and drive the market's growth. In addition to this, rising R&D expenditure will more involvement on novel therapeutics of pompe diseases as this is a very crucial and fatal disease. For Instance, Genethon developed a gene therapy clinical trial for late-onset pompe disease in February 2021 using technologies developed at Genethon. This creates more opportunity in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global pompe disease market over a forecast period.

• High Cost

The huge expenditure of the treatment methods surely hamper the market growth.

This global pompe disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global pompe disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Pompe Disease Market       

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.

The global pompe disease market witnessed a huge negative transition during the COVID-19 pandemic as there was a decline in patient hospitalizations, and only emergency and primary care services are available during COVID-19. Patients with Pompe disease are at very high risk. Thus, COVID-19 significantly impacted the Pompe diseases market. 

Global Pompe Disease Market Scope

The global pompe disease market is segmented on the basis of type, diagnosis, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Classic Infantile Form
• Non-Classic Infantile Form
• Late-Onset Form
• Others

Diagnosis

• Blood Test
• Genetic Test
• Prenatal Test
• Others

Treatment

• Enzyme Replacement Therapy
• Supportive Therapies
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Pompe Disease Market Regional Analysis/Insights

The global pompe disease market is analysed and market size insights and trends are provided by type, diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global pompe disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to advancements in technology for diagnosis of rare disease using ICD and increasing initiatives by the pharmaceutical organizations to generate novel formulation.

Asia-Pacific dominates the market due increasing initiatives taken by the government and pharmaceutical organizations to spread awareness and presence of generic manufacturer.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Pompe Disease Market Share Analysis

The global pompe disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global pompe disease market.

Key players operating in the global pompe disease market include:

• Amicus Therapeutics, Inc (U.S.)
• Audentes Therapeutics (U.S.)
• Novartis AG (Switzerland)
• Fresenius Kabi AG (Germany)
• Akorn Incorporated (U.S.)
• Teva Pharmaceutical Industries Ltd (Israel)
• Mylan N.V (U.S.)
• Johnsons & Johnsons Services Inc (U.S.)
• F. Hoffman-La Roche Ltd. (Switzerland)
• Danaher. (U.S.)
• B.D. (U.S.)
• Chembio Diagnostics (U.S.)
• Sekisui Diagnostics (US)
• Thermo Fisher Scientific (U.S.)
• bioMérieux S.A. (France)

SKU-53834